Copyright
©The Author(s) 2021.
World J Clin Cases. Apr 6, 2021; 9(10): 2228-2237
Published online Apr 6, 2021. doi: 10.12998/wjcc.v9.i10.2228
Published online Apr 6, 2021. doi: 10.12998/wjcc.v9.i10.2228
Table 1 Annual distribution of Gram-positive and Gram-negative bacteria detected in samples
| Year | Strains identified | Gram-positive bacteria, n (%) | Gram-negative bacteria, n (%) | Fungi, n (%) |
| 2006 | 170 | 67 (39.41) | 102 (60.00) | 1 (0.59) |
| 2007 | 232 | 99 (42.67) | 131 (56.46) | 2 (0.86) |
| 2008 | 129 | 62 (48.07) | 65 (50.39) | 2 (1.55) |
| 2009 | 239 | 87 (36.4) | 144 (60.25) | 8 (3.35) |
| 2010 | 293 | 133 (45.39) | 159 (54.26) | 1 (0.34) |
| 2011 | 349 | 152 (43.56) | 194 (55.59) | 3 (0.86) |
| 2012 | 621 | 358 (57.65) | 257 (41.38) | 6 (0.97) |
| 2013 | 606 | 326 (53.8) | 268 (44.22) | 12 (1.98) |
| 2014 | 785 | 441 (56.18) | 329 (41.91) | 15 (1.91) |
| 2015 | 678 | 356 (52.51) | 310 (45.72) | 12 (1.77) |
| 2016 | 785 | 390 (49.68) | 392 (49.94) | 3 (0.38) |
| 2017 | 810 | 400 (49.38) | 401 (49.51) | 9 (1.11) |
| 2018 | 1098 | 560 (51.00) | 508 (46.27) | 30 (2.73) |
| 2019 | 1165 | 525 (45.06) | 571 (49.01) | 69 (5.92) |
| Total | 7960 | 3956 (49.70) | 3831 (48.13) | 173 (2.17) |
Table 2 Pathogens detected annually from 2006 to 2019, n (%)
| 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | Total1 | |
| Staphylococcus aureus | 29 (17.06) | 52 (22.41) | 29 (22.48) | 44 (18.41) | 51 (17.41) | 76 (21.78) | 149 (23.99) | 131 (21.62) | 169 (21.53) | 180 (26.55) | 175 (22.29) | 164 (20.25) | 261 (23.77) | 216 (18.54) | 1726 (21.68) |
| Pseudomonas aeruginosa | 18 (10.59) | 13 (5.6) | 14 (10.85) | 33 (13.81) | 49 (16.72) | 46 (13.18) | 69 (11.11) | 72 (11.88) | 75 (9.55) | 86 (12.68) | 141 (17.96) | 158 (19.51) | 153 (13.93) | 206 (17.68) | 1133 (14.23) |
| Staphylococcus epidermidis | 4 (2.35) | 8 (3.45) | 8 (6.2) | 8 (3.35) | 23 (7.85) | 21 (6.02) | 68 (10.95) | 64 (10.56) | 73 (9.3) | 68 (10.03) | 77 (9.81) | 100 (12.35) | 115 (10.47) | 128 (10.99) | 765 (9.61) |
| Acinetobacter baumannii | 27 (15.88) | 51 (21.98) | 8 (6.2) | 35 (14.64) | 32 (10.92) | 53 (15.19) | 38 (6.12) | 32 (5.28) | 39 (4.97) | 21 (3.1) | 49 (6.24) | 35 (4.32) | 58 (5.28) | 88 (7.55) | 566 (7.11) |
| Enterococcus faecalis | 16 (9.41) | 21 (9.05) | 5 (3.88) | 6 (2.51) | 14 (4.78) | 17 (4.87) | 22 (3.54) | 24 (3.96) | 43 (5.48) | 37 (5.46) | 54 (6.88) | 57 (7.04) | 59 (5.37) | 69 (5.92) | 444 (5.58) |
| Enterobacter cloacae | 8 (4.71) | 13 (5.6) | 10 (7.75) | 20 (8.37) | 16 (5.46) | 14 (4.01) | 32 (5.15) | 33 (5.45) | 39 (4.97) | 49 (7.23) | 38 (4.84) | 45 (5.56) | 45 (4.1) | 51 (4.38) | 413 (5.19) |
| Escherichia coli | 10 (5.88) | 21 (9.05) | 12 (9.3) | 15 (6.28) | 15 (5.12) | 24 (6.88) | 29 (4.67) | 29 (4.79) | 26 (3.31) | 37 (5.46) | 57 (7.26) | 41 (5.06) | 43 (3.92) | 33 (2.83) | 392 (4.92) |
| Klebsiella pneumoniae | 7 (4.12) | 6 (2.59) | 7 (5.43) | 7 (2.93) | 12 (4.1) | 13 (3.72) | 18 (2.9) | 24 (3.96) | 29 (3.69) | 30 (4.42) | 27 (3.44) | 37 (4.57) | 75 (6.83) | 72 (6.18) | 364 (4.57) |
| Proteus mirabilis | 6 (3.53) | 5 (2.16) | 5 (3.88) | 9 (3.77) | 8 (2.73) | 11 (3.15) | 5 (0.81) | 14 (2.31) | 14 (1.78) | 21 (3.1) | 20 (2.55) | 28 (3.46) | 19 (1.73) | 14 (1.2) | 179 (2.25) |
| Enterococcus faecium | 7 (4.12) | 8 (3.45) | 4 (3.1) | 6 (2.51) | 2 (0.68) | 9 (2.58) | 13 (2.09) | 12 (1.98) | 14 (1.78) | 8 (1.18) | 17 (2.17) | 19 (2.35) | 19 (1.73) | 25 (2.15) | 163 (2.05) |
| Sum | 170 | 232 | 129 | 239 | 293 | 349 | 621 | 606 | 785 | 678 | 785 | 810 | 1098 | 1165 | 7960 (100.00) |
Table 3 Comparison of antimicrobial resistance of major pathogens in burn patients, n (%)
| 2006-2011 | 2012-2019 | χ2 | P value | ||||
| Strain | Resistant strains | Strain | Resistant strains | ||||
| Staphylococcus aureus | Oxacillin | 281 | 191 (67.97) | 1445 | 545 (37.72) | 88.0448 | < 0.001 |
| Vancomycin | 281 | 0 (0.00) | 1445 | 0 (0.00) | NA | NA | |
| Enterococcus | Vancomycin | 115 | 13 (11.30) | 492 | 6 (1.22) | 31.265 | < 0.001 |
| Pseudomonas aeruginosa | Cefepime | 173 | 109 (63.01) | 960 | 369 (38.44) | 36.2767 | < 0.001 |
| Ceftazidime | 173 | 78 (45.09) | 960 | 334 (34.79) | 6.7138 | 0.001 | |
| Imipenem | 173 | 79 (45.67) | 960 | 390 (40.63) | 1.5347 | 0.215 | |
| Levofloxacin | 173 | 88 (50.87) | 960 | 349 (36.35) | 13.0306 | < 0.001 | |
| Acinetobacter baumannii | Cefepime | 203 | 181 (89.16) | 360 | 261 (72.50) | 21.3591 | < 0.001 |
| Ceftazidime | 203 | 173 (85.22) | 360 | 255 (70.83) | 14.7418 | < 0.001 | |
| Imipenem | 203 | 135 (66.50) | 360 | 233 (64.72) | 0.1817 | 0.67 | |
| Levofloxacin | 203 | 177 (87.19) | 360 | 186 (51.67) | 71.5236 | < 0.001 |
- Citation: Chen H, Yang L, Cheng L, Hu XH, Shen YM. Distribution and drug resistance of pathogens in burn patients in China from 2006 to 2019. World J Clin Cases 2021; 9(10): 2228-2237
- URL: https://www.wjgnet.com/2307-8960/full/v9/i10/2228.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i10.2228